Checkpoint Capital L.P. Argenx Se Transaction History
Checkpoint Capital L.P.
- $298 Billion
- Q3 2025
A detailed history of Checkpoint Capital L.P. transactions in Argenx Se stock. As of the latest transaction made, Checkpoint Capital L.P. holds 150,000 shares of ARGX stock, worth $136 Million. This represents 37.07% of its overall portfolio holdings.
Number of Shares
150,000
Previous 149,977
0.02%
Holding current value
$136 Million
Previous $82.7 Billion
33.83%
% of portfolio
37.07%
Previous 38.52%
Shares
7 transactions
Others Institutions Holding ARGX
# of Institutions
526Shares Held
26MCall Options Held
590KPut Options Held
320K-
Price T Rowe Associates Inc Baltimore, MD3.64MShares$3.31 Billion0.29% of portfolio
-
Janus Henderson Group PLC London, X02.58MShares$2.34 Billion0.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.19MShares$1.99 Billion2.46% of portfolio
-
Capital World Investors Los Angeles, CA1.96MShares$1.78 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY1.01MShares$918 Million0.01% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $50.2B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...